KUALA LUMPUR, Nov 18 (Bernama) -- AGC Biologics, a global biopharmaceutical contract development and manufacturing organisation, has been selected by three biopharma developers, including the Institute of Science Tokyo, to provide cell therapy services at its Yokohama facility.
AGC Biologics Wins Three Cell Therapy Projects In Japan
AGC Biologics Wins Three Cell Therapy Projects In
Key takeaways
AGC Biologics secured three cell therapy projects in Japan, including work with the Institute of Science Tokyo. The Yokohama facility, operational since July 2025, offers services for various stem cell and CAR-T technologies.
- AGC Biologics was selected by three developers, including the Institute of Science Tokyo, for cell therapy services.
- The Yokohama facility began offering cell therapy services in July 2025.
- Services include process transfer and manufacturing for pre-clinical and clinical trials.
- One project aims to advance virus-specific T-cell therapy for adenovirus infections.
Summarised automatically by AI from the original article by Bernama. AI can make mistakes, so check the original for details.
Story details
- Published
- Section
- news
- Format
- Article
- Original
- bernama.com ↗
Related reporting
2 stories on this topic from 2 sources, oldest first.
- Bernama AGC Biologics Wins Three Cell Therapy Projects In Japan (this story)



